PTGX
Protagonist Therapeutics, IncPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 6 ▼ 1 insider sell $1.7M at $83.68
- Mar 24 to Mar 26 ▼ 3 days of insider sells: $12.2M by 4 insiders, avg $102.97
- Apr 20 ▼ 1 insider sell $184.6K at $105.47
- May 7 to May 12 ▼ 3 days of insider sells: $13.4M by 2 insiders, avg $100.11
- May 29 ▼ 1 insider sell $896.8K at $99.64
- Jun 10 ▼ 1 insider sell $969.1K at $107.68
- Jun 23 ▼ 1 insider sell $1.1M at $117.94
- Aug 10 to Aug 11 ▼ 2 days of insider sells: $14.9M by 1 insider, avg $148.91
- Sep 8 to Sep 10 ▼ 3 days of insider sells: $18.2M by 1 insider, avg $145.92
- Sep 30 ▼ 1 insider sell $8.3M at $141.78
- Oct 12 UBS initiates
- Nov 5 ▲ Protagonist Therapeutics reported Q3 2026 net income of $220.0M ($3.…
Signal stack
Where each data set points today.
- InsidersBEARISH
6 insiders sold $71.9M.
- InstitutionsBULLISH
Q3 2026: 38 added (2 new), 18 trimmed or exited. Largest new: Renaissance Technologies $10.8M.
- AnalystsBULLISH
20 of 21 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −0.5% to 10.24M shares. 16.9 days to cover, ≈15.7% of shares.
- TrendDOWNTREND
11% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | ADD | $151.6M |
| JPMORGAN CHASE & CO | ADD | $48.7M |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | ADD | $45.2M |
| Russell Investments Group, Ltd. | ADD | $30.3M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | DOUBLED | $15.9M |
| FIRST TRUST ADVISORS LP | ADD | $12.7M |
| TD ASSET MANAGEMENT INC | TRIM | $12.1M |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | TRIM | $11.3M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
21 analystsPrice is below the lowest target. Median implies +45%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 6, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Oct 21, 2026 | TD Cowen MAINTAIN | Buy |
| Oct 12, 2026 | UBS INITIATE | Buy |
| Sep 1, 2026 | Barclays MAINTAIN | Overweight |
| Sep 1, 2026 | BMO Capital MAINTAIN | Outperform |
| Aug 31, 2026 | Citigroup MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Ali Asif Chief Financial Officer Sep 30, 2026 | EXERCISE | $666.0K |
Ali Asif Chief Financial Officer Sep 30, 2026 | EXERCISE | $300.3K |
Ali Asif Chief Financial Officer Sep 30, 2026 | EXERCISE | $64.6K |
Ali Asif Chief Financial Officer Sep 30, 2026 | EXERCISE | $359.7K |
Ali Asif Chief Financial Officer Sep 30, 2026 | SELL | $1.8M |
Ali Asif Chief Financial Officer Sep 30, 2026 | SELL | $6.5M |
PATEL DINESH V PH D President and CEO Sep 10, 2026 | EXERCISE | $157.1K |
PATEL DINESH V PH D President and CEO Sep 10, 2026 | SELL | $1.0M |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.36 | -$0.35–$1.85 | +387.8% | $58.3M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 2 bullish · 2 bearish · 3 mixed · 4 neutral- BULLISH 8-KNov 5, 2026
Protagonist Therapeutics reported Q3 2026 net income of $220.0M ($3.07 diluted EPS) on $274.4M in…
The MIMRYLO approval milestone and opt-out payments have transformed Protagonist into a cash-flow-positive, royalty-generating biotech. Watch for ICOTYDE royalty ramp from J&J's global launches and…
- MIXED INST-CLUSTERNov 4, 2026
In Q3 2026, five asset managers added to their PTGX positions totaling $7.2M in net buying, while…
The large Dimensional Fund Advisors exit dominates the cluster's dollar flow, suggesting a conviction shift by a major holder. Monitor upcoming 13F filings and any corporate announcements for…
- NEUTRAL SC 13G/AOct 27, 2026
BlackRock filed an amended Schedule 13G disclosing beneficial ownership of 9,834,146 shares of…
BlackRock's passive stake increase is routine for a large index fund manager. No prior 13D conversion or activist intent is signaled. Monitor for any future 13D filing if BlackRock's engagement…
- BEARISH 144Aug 10, 2026
CEO Dinesh Patel filed a Form 144 notice of intent to sell 225,000 shares of Protagonist…
CEO's large proposed sale (~$33.6M) signals potential insider distribution; monitor for actual Form 4 filings to confirm execution. The sale is concurrent with option exercise, suggesting a planned…
All PTGX filing & press-release reports (11)
- 8-K reportNov 5, 2026
- INST-CLUSTER reportNov 4, 2026
- SC 13G/A reportOct 27, 2026
- 144 reportAug 10, 2026
- 8-K reportJun 18, 2026
- INST-CLUSTER reportJun 12, 2026
- CLUSTER reportMay 8, 2026
- CLUSTER reportMay 8, 2026
- 144 reportMay 12, 2026
- 8-K reportMay 5, 2026
- 8-K reportFeb 25, 2026